Analysts Are Bullish on These Healthcare Stocks: Oric Pharmaceuticals (ORIC), Option Care Health (OPCH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report), Option Care Health (OPCH – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oric Pharmaceuticals (ORIC)
In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. The company’s shares closed last Monday at $11.71.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of
Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $20.50, implying an 85.2% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Option Care Health (OPCH)
In a report released today, Matt Larew from William Blair reiterated a Buy rating on Option Care Health. The company’s shares closed last Monday at $36.09.
According to TipRanks.com, Larew is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Option Care Health with a $38.71 average price target.
Gilead Sciences (GILD)
Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Monday at $149.83.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $155.39 average price target, a 4.3% upside from current levels. In a report issued on February 10, UBS also maintained a Buy rating on the stock with a $155.00 price target.
